KR20110019324A - Bokbun free oil composition, its use and preparation method - Google Patents
Bokbun free oil composition, its use and preparation method Download PDFInfo
- Publication number
- KR20110019324A KR20110019324A KR1020100054633A KR20100054633A KR20110019324A KR 20110019324 A KR20110019324 A KR 20110019324A KR 1020100054633 A KR1020100054633 A KR 1020100054633A KR 20100054633 A KR20100054633 A KR 20100054633A KR 20110019324 A KR20110019324 A KR 20110019324A
- Authority
- KR
- South Korea
- Prior art keywords
- bokbunja
- oil
- acid
- composition
- oil composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title description 13
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 34
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 33
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 24
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 20
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 11
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 11
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 11
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 11
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 10
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000005642 Oleic acid Substances 0.000 claims abstract description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 9
- 229920001968 ellagitannin Polymers 0.000 claims abstract description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 9
- 235000021313 oleic acid Nutrition 0.000 claims abstract description 9
- 239000008117 stearic acid Substances 0.000 claims abstract description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 206010003645 Atopy Diseases 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 230000003712 anti-aging effect Effects 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 238000007731 hot pressing Methods 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 abstract description 4
- 239000003921 oil Substances 0.000 description 61
- 235000019198 oils Nutrition 0.000 description 61
- 230000000694 effects Effects 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000003579 anti-obesity Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002035 hexane extract Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 aceitol Chemical compound 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241001618264 Rubus coreanus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001092459 Rubus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229940098330 gamma linoleic acid Drugs 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 229940098695 palmitic acid Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
Landscapes
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 공액리놀레산을 함유하는 복분자유 조성물, 이의 용도 및 제조방법에 관한 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산, 올레산 및 리놀레산으로 이루어진 그룹으로부터 선택되는 1종 이상의 성분을 추가로 함유하는 복분자유를 포함하는 조성물, 이의 용도 및 그 제조방법에 관한 것이다.The present invention relates to bokbunja oil composition containing conjugated linoleic acid, omega-3, omega-6, ellagitannins, ellagic acid, palmitic acid, stearic acid, oleic acid And it relates to a composition comprising bokbunja oil further containing at least one component selected from the group consisting of linoleic acid, uses thereof and a method of preparing the same.
Description
본 발명은 공액리놀레산을 함유하는 복분자유 조성물, 이의 용도 및 제조방법에 관한 것으로서, 상기 조성물은 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산으로 이루어진 그룹으로부터 선택되는 1종 이상의 성분을 추가로 함유할 수 있으며, 항산화, 항노화, 항비만 또는 항아토피 효과를 갖는다. 또한, 본 발명은 활성을 갖는 물질이 고함량으로 포함된 복분자유를 수득하는 방법을 제공하는 것을 목적으로 한다.
The present invention relates to a bokbunja oil composition containing conjugated linoleic acid, its use and preparation method, wherein the composition is omega-3, omega-6, ellagitannins, ellagic acid, palmitic acid It may further contain one or more components selected from the group consisting of stearic acid and oleic acid, and have antioxidant, anti-aging, anti-obesity or anti-atopic effects. It is also an object of the present invention to provide a method for obtaining bokbunja oil containing a high content of an active substance.
복분자(Rubus coreanus Miquel, Korean black berry)는 장미과에 속하며, 동의보감에서는 보간신, 명목, 이뇨, 정력증강 효과가 있다고 알려져 있다. 최근 복분자 열매는 식품 또는 음료의 첨가제나 주조에 많이 사용되고 있다.Bokbunja ( Rubus coreanus Miquel, Korean black berry) belongs to the family Rosaceae, and in synonymous gagam is known to have interpolation, nominal, diuretic, energetic enhancement. Recently, bokbunja fruit has been used a lot of additives or casting of food or beverage.
우리나라 농가에서 경쟁적으로 재배되는 복분자는 주로 냉동열매로 소량 판매하거나 농축액으로 판매하며, 원액의 수율을 높이고 살균을 동시에 하기 위하여 소규모 영농조합에서는 탱크시설에서 물:복분자를 1:1의 비율로 넣고 100 ℃ 이상으로 끓여 농축액을 열수 추출하는 방법을 사용한다. 그러나, 이러한 열수추출방법은 복분자 중의 비타민 성분을 파괴시킨다는 문제점이 있다. 또한, 복분자씨를 포함한 잔사는 대부분 버려지고 있는 실정이다.Competitive cultivated cultivated in Korean farms are mainly sold as frozen fruit or as a concentrated liquid.In order to increase the yield of raw liquid and to sterilize at the same time, small farming cooperatives put water: bokbunja at a ratio of 1: 1 in tank facilities. Boil at a temperature higher than ℃ to extract hot water. However, this hot water extraction method has a problem that destroys the vitamin component in the bokbunja. In addition, most of the residues including bokbunja are discarded.
일반적으로 복분자의 물 또는 유기용매 추출물이 항암, 항우울증 치료에 사용되는 약학 조성물이 보고된 바 있으나(각각 한국특허공개공보 10-2005-0113290호 및 한국특허공개공보 10-2007-0108724호), 항산화 활성이 있는 엘라그산 등에 대해 시사하고 있지 아니하며, 복분자씨에 대해서도 개시하고 있지 아니하다. Generally, pharmaceutical compositions in which water or organic solvent extracts of bokbunja are used for anticancer and antidepressant treatment have been reported (Korean Patent Laid-Open Publication Nos. 10-2005-0113290 and 10-2007-0108724, respectively). It does not suggest ellagic acid or the like having antioxidant activity, nor does it disclose any bokbunja seeds.
또한, 한국특허출원 10-2006-0033340호는 복분자로부터 항산화 활성 물질을 분리하는 방법에 대한 발명이나, 열수 추출법을 사용하고 있다는 한계가 있으며, 복분자씨의 이용 및 본 발명의 항산화 물질들의 종류에 대해 개시하고 있지 않다.
In addition, Korean Patent Application No. 10-2006-0033340 has a limitation on the invention of separating antioxidant active substances from bokbunja, or the use of hot water extraction method, and the use of bokbunja seeds and the types of antioxidant substances of the present invention. It is not starting.
이에, 본 발명자는 복분자 항산화 유기활성 성분을 연구하던 중, 복분자씨에서 추출한 복분자유 중에 다량의 공액리놀레산이 존재한다는 것을 최초로 발견하였고, 이 밖에도 엘라지탄닌류 및 알레그산과 같은 활성성분이 다량 존재한다는 것을 발견하였으며, 이들 활성 성분의 파괴를 최소화하는 추출방법을 도출함으로써 본 발명을 완성하였다.Thus, the present inventors first discovered that a large amount of conjugated linoleic acid is present in bokbunja oil extracted from bokbunja seeds during the study of bokbunja antioxidant organic active ingredient, in addition to the presence of a large amount of active ingredients such as ellagitannins and allegic acid It was found that the present invention was completed by deriving an extraction method which minimizes the destruction of these active ingredients.
따라서, 본 발명은 공액리놀레산을 함유하는 복분자유 조성물, 그 용도 및 제조방법을 제공하기 위한 것으로서, 상기 조성물은 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산으로 이루어진 그룹으로부터 선택되는 1종 이상의 성분을 추가로 함유하는 복분자유를 포함할 수 있다. Accordingly, the present invention is to provide a bokbunja oil composition containing conjugated linoleic acid, its use and preparation method, the composition is omega-3, omega-6, ellagitannins, ellagic acid And bokbunja oil further containing at least one component selected from the group consisting of palmitic acid, stearic acid and oleic acid.
또한, 본 발명은 우리나라에서 많이 재배되고 있는 복분자로부터 복분자유를 추출하여 항산화, 항노화, 항비만 또는 항아토피 활성을 갖는 물질이 고함량으로 포함된 복분자유를 제공하는 것을 목적으로 한다. 또한, 복분자씨로부터 상기 활성 성분이 고함량으로 포함된 복분자유를 추출하는 방법을 제공하는 것을 목적으로 한다.
In addition, the present invention is to provide a bokbunja oil containing a high content of a substance having antioxidant, anti-aging, anti-obesity or anti-atopic activity by extracting bokbunja oil from bokbunja cultivated in Korea. It is also an object of the present invention to provide a method for extracting bokbunja oil containing a high content of the active ingredient from bokbunja seed.
본 발명은 공액리놀레산을 함유하는 복분자유를 포함하는 조성물을 그 특징으로 한다.The present invention is characterized by a composition comprising bokbunja oil containing conjugated linoleic acid.
또한, 본 발명은 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산으로 이루어진 그룹으로부터 선택되는 1종 이상의 성분을 추가로 함유하는 복분자유 조성물을 제공함으로써, 항산화, 항노화, 항비만 또는 항아토피 효과가 우수한 조성물을 제공할 수 있다.In addition, the present invention further contains at least one component selected from the group consisting of omega-3, omega-6, ellagitannins, ellagic acid, ellagic acid, palmitic acid, stearic acid and oleic acid. By providing a bokbunja oil composition, it is possible to provide a composition excellent in antioxidant, anti-aging, anti-obesity or anti-atopic effect.
또한, 복분자씨를 냉압착법, 온압착법, 저온압착법 및 용매 추출법으로 이루어진 그룹으로부터 선택되는 1종 이상의 추출법을 수행하여 공액리놀레산(CLA)을 포함하는 복분자유을 추출하는 방법을 제공함으로써 상기 활성성분이 고함량으로 포함된 복분자유를 수득할 수 있다.In addition, by performing one or more extraction methods selected from the group consisting of cold compression method, hot compression method, low temperature compression method and solvent extraction method of the bokbunja seed to extract the bokbunja oil containing conjugated linoleic acid (CLA) by Bokbun free oil contained in this high content can be obtained.
또한, 본 발명에서는 상기 공액리놀레산(CLA)을 포함하는 복분자유 조성물을 포함하는 건강기능식품, 식품, 화장품, 산화방지제, 노화 또는 아토피 예방 및 치료용 약제, 비만 예방 및 치료용 약제를 제공할 수 있다.
In addition, the present invention can provide a health functional food, food, cosmetics, antioxidants, aging or atopic prophylaxis and treatment, including the conjugated linoleic acid (CLA) containing bokbunja oil composition, obesity prevention and treatment have.
본 발명은 복분자로부터 항산화, 항노화, 항비만 또는 항아토피 활성을 갖는 물질이 고함량으로 포함된 복분자유를 추출하여, 이를 산화작용으로 인한 질환, 아토피 질환 등의 예방 및 치료에 사용될 수 있으며, 종래 복분자로부터 과즙을 추출한 후 남은 잔사와 함께 버려지던 복분자씨로부터 항산화 활성을 갖는 정유성분을 추출하여 활용함으로써 자원 낭비를 줄일 수 있다는 장점이 있다.
The present invention extracts bokbunja oil containing a high content of antioxidant, anti-aging, anti-obesity or anti-atopic activity from bokbunja, it can be used for the prevention and treatment of diseases caused by oxidation, atopic diseases, etc. After extracting the juice from the conventional bokbunja and extracting the essential oil component having an antioxidant activity from the bokbunja seed that was discarded with the residue has the advantage of reducing the resource waste.
도 1은 종래 복분자 헥산 추출물(복분자 A), 실시예 2의 복분자유(복분자 B) 및 포도씨유 중의 지방산 성분을 분석한 결과이다 [PA: 팔미트산, ST: 스테아르산, OA: 올레산, LA: 리놀레산, LNA: 리놀렌산, CLA: 공액리놀레산].
도 2는 DPPH 분석 결과를 도시한 것이다.
도 3은 MTT 실험 결과를 도시한 것이다.
도 4는 MMP-1 저해효과 실험 결과를 도시한 것이다.
도 5는 베타헥소아미나디아제 유도제(A23187) 10μM, 실시예 2의 복분자유 각 농도군 및 대조군의 β-헥소아미니다아제 방출율을 측정한 결과를 도시한 것이다.1 is a result of analyzing the fatty acid components in the conventional bokbunja hexane extract (bokbunja A), Bokbunja oil (bokbunja B) and grape seed oil of Example 2 [PA: palmitic acid, ST: stearic acid, OA: oleic acid, LA : Linoleic acid, LNA: linolenic acid, CLA: conjugated linoleic acid].
2 shows the results of DPPH analysis.
Figure 3 shows the results of the MTT experiment.
Figure 4 shows the results of the MMP-1 inhibitory effect experiment.
Figure 5 shows the results of measuring the β-hexamiminidase release rate of 10 μM of beta hexoamidase inducer (A23187), Bokbunja oil concentration of Example 2 and the control group.
본 발명은 공액리놀레산(conjugated linoleic acid, CLA)을 함유하는 복분자유 조성물에 관한 것이다. 본 발명에서, 복분자유 중 총 지방산의 함량을 기준으로, 공액리놀레산의 함량이 5 내지 30 중량%인 것을 특징으로 하며, 보다 구체적으로 그 함량은 10 내지 25 중량%일 수 있다.The present invention relates to a bokbun free oil composition containing conjugated linoleic acid (CLA). In the present invention, the content of conjugated linoleic acid is 5 to 30% by weight based on the total fatty acid content in bokbunja oil, more specifically, the content may be 10 to 25% by weight.
본 발명에서, 상기 조성물은 오메가-3, 오메가-6, 엘라지탄닌류 (ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산으로 이루어진 그룹으로부터 선택되는 1종 이상의 성분을 추가로 함유하는 복분자유를 포함할 수 있으며, 이 밖에도 단백질, 식이섬유를 함유할 수 있다.In the present invention, the composition adds one or more components selected from the group consisting of omega-3, omega-6, ellagitannins, ellagic acid, ellagic acid, palmitic acid, stearic acid and oleic acid It may contain bokbunja oil containing, and may also contain protein, dietary fiber.
특히, 본 발명의 복분자유 조성물은 공액리놀레산 5 ~ 30 중량%, 팔미트산 0.8 ~ 3 중량%, 스테아르산 0.5 ~ 1.5 중량%, 올레산 5 ~ 15 중량%, 리놀레산 35 ~ 65 중량%, 리놀렌산 15 ~ 35 중량%을 함유하는 것이 보다 바람직하다.In particular, the bokbunja oil composition of the present invention is 5 to 30% by weight of conjugated linoleic acid, 0.8 to 3% by weight of palmitic acid, 0.5 to 1.5% by weight of stearic acid, 5 to 15% by weight of oleic acid, 35 to 65% by weight of linoleic acid, linolenic acid 15 It is more preferable to contain -35 weight%.
본 발명에서, 상기 복분자유는 복분자씨로부터 추출될 수 있으며, 특히 복분자유는 복분자를 착즙하고 남은 잔사 중의 복분자씨로부터 분리될 수 있다.In the present invention, the bokbunja oil can be extracted from the bokbunja seed, in particular bokbunja oil can be separated from the bokbunja seeds in the remaining residue after bokbunja juice.
공액리놀레산은 항암, 항동맥경화, 항비만, 항염증 및 항산화 작용에 대하여 보고된 바 있으며, 특히 비만세포 분화 억제효과 및 체지방량 감소에 도움을 주는 것으로 알려져 있으나, 복분자로부터 상기 성분이 검출된 것은 이번이 최초이다.Conjugated linoleic acid has been reported for anti-cancer, anti-arteriosclerosis, anti-obesity, anti-inflammatory and anti-oxidant activity. Especially, it is known that it helps to inhibit mast cell differentiation and decrease body fat mass. This is the first time.
오메가-3는 오메가-3 지방산이라고도 불리며, 불포화지방산에 속한다. α-리놀렌산(ALA), 에이코사펜타노산(EPA) 및 도코사헥사에노산(DHA) 성분 등이 포함된다. 항산화활성, 항암활성, 심혈관계 질환의 예방 또는 치료 효능, 면역력 증강, 뇌기능 개선, 퇴행성 관절염의 예방 또는 치료 등에 유효한 성분으로 알려져 있다.Omega-3 is also called omega-3 fatty acid and belongs to unsaturated fatty acid. α-linolenic acid (ALA), eicosaptanoic acid (EPA) and docosahexaenoic acid (DHA) components and the like. It is known as an effective ingredient for antioxidant activity, anticancer activity, prevention or treatment of cardiovascular disease, enhancement of immunity, improvement of brain function, prevention or treatment of degenerative arthritis.
오메가-6는 오메가-6 지방산이라고도 불리며, 리놀레산, 감마-리놀레산, 아라키돈산 성분 등이 포함된다. 세포막의 생합성, 혈관, 면역체계 등의 생리조절 등에 관여하는 성분으로 알려져 있으며, 혈액 내의 콜리스테롤치를 낮추어 심장질환의 발병위험을 낮출 수 있으며, 면역 증강효과, 혈당 조절효과, 비만 예방 효과, 노화 예방 효과, 피부건강 유지 효과가 있다.Omega-6 is also called omega-6 fatty acid and includes linoleic acid, gamma-linoleic acid, arachidonic acid components and the like. It is known to be involved in the biosynthesis of cell membranes, physiological control of blood vessels, immune system, etc., and it lowers the cholesterol level in the blood to lower the risk of heart disease, immune enhancing effect, blood sugar control effect, obesity prevention effect, and aging prevention. It is effective in maintaining skin health.
엘라지탄닌류(ellagitannins)는 항산화 효과, 간기능 개선 효과, 항암 효과, 피부 보호 효과, 항알러지 효과를 갖는 성분군의 하나로 알려져 있다. Ellagitannins are known as one of a group of ingredients having an antioxidant effect, liver function improvement effect, anticancer effect, skin protection effect and anti-allergic effect.
엘라그산(ellagic acid)은 폴리페놀 4개의 링으로 구성되어 있으며, 식물체 내에서는 전구물질인 엘라지탄닌 형태로 존재한다. 항산화, 항바이러스, 항돌연변이, 항암기능을 가지고 있으며, 유방 및 식도, 피부, 결장, 전립선과 췌장에서의 암세포 활동을 억제하는 역할을 하는 것으로 알려져 있다.Ellagic acid (ellagic acid) consists of four rings of polyphenols, which are present in the plant in the form of ellagitannins. It has antioxidant, antiviral, antimutagenic and anticancer functions and is known to inhibit cancer cell activity in breast and esophagus, skin, colon, prostate and pancreas.
본 발명에서, 상기 조성물은 항산화, 항노화 또는 항아토피 효능을 갖는다. 또한, CLA의 항비만 효과가 알려져 있으므로 항비만 효과도 포함할 수 있다.In the present invention, the composition has antioxidant, anti-aging or anti-atopic efficacy. In addition, since the anti-obesity effect of CLA is known, it may also include an anti-obesity effect.
본 발명은 또한 복분자유로부터 추출되고, 공액리놀레산(conjugated linoleic acid, CLA)을 포함하는 조성물에 관한 것으로서, 상기 조성물은 항산화, 항노화, 항비만 또는 항아토피 효능을 갖는다.The present invention also relates to a composition extracted from bokbunja oil and comprising conjugated linoleic acid (CLA), wherein the composition has antioxidant, anti-aging, anti-obesity or anti-atopic efficacy.
본 발명은 복분자씨를 냉압착법, 온압착법, 저온압착법 및 용매 추출법으로 이루어진 그룹으로부터 선택되는 1종 이상의 추출법을 수행하여 공액리놀레산(CLA)을 포함하는 복분자유을 추출하는 방법에 관한 것이다. The present invention relates to a method for extracting bokbunja oil containing conjugated linoleic acid (CLA) by performing one or more extraction methods selected from the group consisting of cold pressing, hot pressing, low temperature pressing and solvent extraction.
본 발명에서, 냉압착법이란 열을 가할 때 흘러나오는 씨를 열처리 하지 않고 바로 압착하여 기름을 얻는 방법으로 열을 가할 때 색소, 방향, 및 검(Gum)질 등이 기름 안에 흘러 나와 기름의 빛깔이 진하고 맛이 나쁠 때가 있으므로 좋은 기름을 얻기 위해 파쇄한 것을 열처리하지 않고 곧 압착하는 방법이며, 온압착법이란, 100 ~ 250 ℃의 고온에서 볶은 후 쪄서 압착하는 방법이고, 저온압착법이란, 43 ℃ 이하로 압착하여 기름을 짜내는 방법이다. 또한, 상기 용매 추출법은 n-헥산 등의 용매를 사용하여 추출하는 방법이다.In the present invention, the cold pressing method is a method of directly compressing the seed flowing out when heat is applied without obtaining heat treatment to obtain oil, and when the heat is applied, pigments, fragrances, gums, etc. flow out into the oil and the color of the oil is increased. Because it is thick and sometimes tastes bad, it is a method of immediately squeezing a crushed product without heat treatment in order to obtain good oil. The hot pressing method is a method of steaming and squeezing after roasting at a high temperature of 100 to 250 ° C. It is a method of squeezing oil by compressing as follows. In addition, the said solvent extraction method is a method of extracting using solvents, such as n-hexane.
본 발명에서, 복분자(Rubus coreanum fruit) 10 중량부당 5 내지 100 중량부의 물을 넣고 착즙하여 과즙을 수득하며, 착즙 후의 잔사를 압착하여 추가로 과즙을 얻을 수 있다. 상기 수득된 과즙을 감압 농축하여 용매 성분을 제거한 후, 건조시켜 복분자씨를 분리한 후 이를 체 등을 이용하여 분리하였으며, 이를 원심분리하여 복분자씨만을 분리할 수 있다. 상기 복분자씨를 오일러버형 또는 익스펠라형의 착유기를 사용하여 80 ~ 150 ℃ (보다 바람직하기로는 100 ~ 130 ℃)에서 5 ~ 40분간 압착하여 공액리놀레산을 포함하는 복분자유를 얻을 수 있다.In the present invention, the bokbunja (
본 발명의 공액리놀레산을 포함하는 복분자유 조성물은 천연물 유래의 물질로서 독성 및 부작용이 거의 없다.Bokbun-free oil composition comprising conjugated linoleic acid of the present invention is a substance derived from natural products with little toxicity and side effects.
본 발명은 복분자유 조성물을 유효성분으로 함유하는 노화 또는 아토피 예방 및 치료용 약제, 산화방지제, 비만 예방 및 치료용 약제를 제공한다.The present invention provides an agent for preventing and treating aging or atopy, an antioxidant, and an agent for preventing and treating obesity, containing the bokbunja oil composition as an active ingredient.
본 발명에 따른 약제는, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 복분자유를 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에이스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘카보네이트(calcium carbonate), 수크로오스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁액, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 웨텝솔(witepsol), 마크로골, 트윈(tween)61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 또한, 비경구적으로 국소 적용할 수 있는 연고제, 액제, 패취제, 드레싱제, 스프레이제 등과 같은 피부외용제 형태로 투여될 수 있다. The medicaments according to the invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. have. Carriers, excipients, and diluents that may be included in compositions comprising bokbunja oil include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, aceitol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient such as starch, calcium carbonate, sucrose or lactose, It is prepared by mixing gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used. In addition, it may be administered in the form of external skin preparations such as ointments, liquids, patches, dressings, sprays and the like that can be topically applied topically.
본 발명에 따른 공액리놀레산이 함유된 복분자유 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서 본 발명의 복분자유 조성물은 1일 0.0001 내지 200 ㎎/㎏, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the conjugated linoleic acid-containing bokbunja oil composition according to the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route and duration of administration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the bokbunja oil composition of the present invention is preferably administered at 0.0001 to 200 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
또한, 본 발명은 상기 복분자유 조성물을 유효성분으로 포함하는 건강기능식품을 제공한다. 상기 유효성분 이외에 식품학적으로 허용 가능한 식품보조 첨가제를 첨가할 수 있다. 상기 건강기능식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.In addition, the present invention provides a health functional food comprising the bokbunja oil composition as an active ingredient. In addition to the active ingredient, a food acceptable additive may be added. The health functional food includes, for example, various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
이때, 건강기능식품 중의 복분자유의 양은 전체 식품 중량의 0.01 내지 20 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 15 g, 바람직하게는 5 내지 12 g의 비율로 가할 수 있다.At this time, the amount of Bokbunja oil in the health functional food may be added to 0.01 to 20% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 15 g, preferably 5 to 12 g based on 100 ml. .
본 발명의 건강기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 복분자유 조성물을 함유하는 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 함유할 수 있다. 상술한 천연 탄수화물의 예로는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 솔비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물, 예를 들어 레바우디오시드 A, 글리시르히진 등; 및 합성 향미제, 예를 들어 사카린, 아스파르탐 등을 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 2 g, 바람직하게는 약 1 내지 1.5 g이다.The health functional beverage composition of the present invention has no particular limitation on the other components besides containing the bokbunja oil composition as essential ingredients in the indicated proportions, and may contain additional ingredients such as various flavoring agents or natural carbohydrates as in general beverages. Can be. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent other than the above-mentioned, a natural flavoring agent, taumartin, a stevia extract, for example, rebaudioside A, glycyrrhizin, etc .; And synthetic flavoring agents such as saccharin, aspartame and the like. The proportion of said natural carbohydrates is generally about 1 to 2 g, preferably about 1 to 1.5 g, per 100 ml of the composition of the present invention.
상기 외에 본 발명의 복분자유 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 복분자유은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이때, 첨가제의 비율은 그다지 중요하지는 않지만 본 발명의 복분자유 100 중량부 당 0.1 내지 약 30 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the bokbunja oil composition of the present invention is various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, Protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like. In addition, the bokbunja oil of the present invention may contain a fruit flesh for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. At this time, the ratio of the additive is not very important but is generally selected from the range of 0.1 to about 30 parts by weight per 100 parts by weight of bokbunja oil of the present invention.
또한, 본 발명은 복분자유 조성물을 유효성분으로 함유하는 화장품을 제공한다.The present invention also provides a cosmetic containing the bokbunja oil composition as an active ingredient.
상기 화장품의 경우, 복분자유를 기초제품 화장료(화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩, 비누), 바디제품 화장료(바디 로션, 바디 오일, 바디 젤, 비누), 색조제품 화장료(파운데이션, 립스틱, 마스카라, 메이크업 베이스), 두발제품 화장료(샴푸, 린스, 헤어 컨디셔너, 헤어 젤) 등에 화장료의 건조중량에 대하여 0.05 ~ 20.0 중량% 함량으로 배합하여 사용할 수 있다.
In the case of the cosmetics, Bokbun Free oil based cosmetic products (cosmetics, creams, essences, cleansing foam, cleansing water, packs, soaps), body products cosmetics (body lotion, body oils, body gels, soaps), color cosmetics (foundation) , Lipstick, mascara, makeup base), hair cosmetics (shampoo, rinse, hair conditioner, hair gel) and the like can be used in combination with 0.05 to 20.0% by weight relative to the dry weight of the cosmetic.
이하, 본 발명에 따르는 실시예 및 본 발명에 따르지 않는 비교예를 통하여 본 발명을 보다 상세히 설명하나, 본 발명의 범위가 하기 제시된 실시예에 의해 제한되는 것은 아니다.
Hereinafter, the present invention will be described in more detail through examples according to the present invention and comparative examples not according to the present invention, but the scope of the present invention is not limited to the examples given below.
<< 제조예Production Example 1> 복분자씨 분리 1> Bokbunja Seed Separation
전라북도 고창지역에서 재배된 복분자 과실(Rubus coreanum fruit) 1 kg을 물 1 kg에 넣고 상온에서 2시간 동안 1차 착즙하여 과즙을 800 g 수득하였다. 1차 착즙 후의 잔사를 진액압착기에 넣고 압착하여 복분자 농축액을 100 g 추가로 수득하였다. The bokbunja fruit grown in North Jeolla Province Gochang region (
1차 착즙 후의 잔사 및 압착 후의 잔사를 모아 진공회전 농축기로 감압 농축하여 용매 성분을 제거한 후, 열풍 건조시켜 복분자씨를 분리한 후 이를 체 진동기에 넣고 직경 0.1 mm 체에 털어 분리하였으며, 이를 다시 원심분리기에 넣고 3000 rpm에서 20분 동안 원심분리하여 복분자씨만을 분리하였다(100 g).
The residues after the first juice and the residues after compression were collected and concentrated under reduced pressure with a vacuum rotary concentrator to remove the solvent components, followed by hot air drying to separate the bokbunja seeds, which were placed in a sieve vibrator and shaken on a sieve of 0.1 mm in diameter. Into bokbunja seeds were separated by centrifugation at 3000 rpm for 20 minutes (100 g).
<< 실시예Example 1> 1> 복분자유Bokbun Free 제조 Produce
복분자씨 20 kg을 온도 센서가 장착된 엑스펠라형 착유기에 넣고 자동온도조절기를 120 ℃에서 맞춰놓고 예열하였다. 복분자씨를 호퍼에 밀어넣고 착유기를 20분간 압착하여 공액리놀레산을 함유하는 복분자유 2 kg을 추출하였다(수율 10%). 20 kg of Bokbunja seeds were placed in an XPeller type milking machine equipped with a temperature sensor and preheated with the thermostat set at 120 ° C. Bokbunja seed was pushed into the hopper and the milking machine was pressed for 20 minutes to extract 2 kg of Bokbunja oil containing conjugated linoleic acid (yield 10%).
<< 실시예Example 2> 2> 복분자유Bokbun Free -- 헥산Hexane 추출 제조 Extract manufacturer
복분자씨 20 kg을 그라인더로 3000 rpm에서 분쇄 후 n-헥산을 첨가하고 잘 흔들어 주었다. 24시간 후에 45 ℃에서 1시간 동안 감압농축기로 감압 농축 후 증발 건조시켜 공액리놀레산을 함유하는 복분자유 헥산 추출물 1.9 kg을 수득하였다(수율: 9.5%).20 kg of bokbunja seeds were ground with a grinder at 3000 rpm, and n-hexane was added thereto and shaken well. After 24 hours, the mixture was concentrated under reduced pressure with a vacuum condenser for 1 hour at 45 ° C., followed by evaporation to dryness, to obtain 1.9 kg of bokbunja oil hexane extract containing conjugated linoleic acid (yield: 9.5%).
<< 실험예Experimental Example 1> 1> 복분자유의Bokbun free 성분 분석 Ingredient analysis
기존 복분자 헥산 추출물[Bioresource Technology 99 "Characterization of seed oils from fresh Bokbunja(Rubus coreanus Miq.) and wine processing waste" (2008) 2852-2856, 비교예 1], 실시예 1에서 수득된 복분자유, 실시예 2에서 수득된 복분자유-헥산 추출 및 포도씨유에 대하여 가스 크로마토그래피법을 이용하여 성분 분석을 실시하였으며, 그 결과는 표 1과 도 1에 나타내었다. Existing Bokbunja hexane extract [Bioresource Technology 99 "Characterization of seed oils from fresh Bokbunja (Rubus coreanus Miq.) And wine processing waste" (2008) 2852-2856, Comparative Example 1], Bokbunja oil obtained in Example 1, Example Component analysis was performed using gas chromatography on bokbunja free-hexane extract and grape seed oil obtained in 2, the results are shown in Table 1 and FIG.
상세한 가스크로마토그래피 조건 및 실험과정은 하기와 같다:Detailed gas chromatography conditions and experimental procedures are as follows:
지방산 분석에 사용된 컬럼은 수펠코왁스-10 퓨즈드 실리카 캐필러리 컬럼(Supelcowax-10 fused silica capillary column, 100m X 0.25 mm i.d., 0.2 μm 필름 두께; Supelco, Inc., Bellefonte, PA, USA)을 사용하였으며 가스 속도(helium)는 1.2 mL/min로 흘려주었다. The column used for fatty acid analysis was a Supelcowax-10 fused silica capillary column (100 m × 0.25 mm id, 0.2 μm film thickness; Supelco, Inc., Bellefonte, PA, USA) Was used and the gas velocity (helium) was flowed at 1.2 mL / min.
컬럼 오븐의 온도는 190 ℃부터 240 ℃까지 분당 4 ℃씩 올려주었다. 시료의 인젝터(투입부, injector)와 검출부(detector)의 온도는 260 ℃로 맞춰주었다. 시료의 투입은 1 μL를 넣어주고 시료 시료는 1/50만 컬럼 내로 들어가게 설정하여 진행하였다.The temperature of the column oven was raised by 4 ℃ per minute from 190 ℃ to 240 ℃. The temperature of the injector and detector of the sample was set at 260 ° C. 1 μL of the sample was added and the sample sample was set to enter 1 / 500,000 column.
<< 실험예Experimental Example 2> 항산화 활성 실험 2> antioxidant activity experiment
가. DPPH 분석end. DPPH Analysis
복분자유의 항산화력을 측정하기 위하여 DPPH 분석을 진행하였다. 복분자유의 농도에 따른 항산화능을 측정하기 위하여, 아스코르브산 100μg/mL, 실시예 1의 복분자씨유 10μg/mL, 100μg/mL, 1000μg/mL, 실시예 2의 복분자씨유(헥산 추출) 10μg/mL, 100μg/mL, 1000μg/mL로 샘플을 준비하고, 96-웰 프레이트에 상기 샘플을 10 μL씩 넣은 후, 거기에 DPPH(1,1-diphenyl-2-picrylhydrazyl) 시약을 190 μL씩 첨가하였다. 그 후 ELISA 515nm에서 흡광도를 측정하였다. DPPH analysis was performed to measure the antioxidant activity of bokbun free oil. In order to measure the antioxidant activity according to the concentration of bokbunja oil, ascorbic acid 100μg / mL, bokbunja seed oil of Example 1 10μg / mL, 100μg / mL, 1000μg / mL, bokbunja seed oil (hexane extraction) of Example 2 10μg / Samples were prepared at mL, 100 μg / mL, and 1000 μg / mL, and 10 μL of the sample was added to a 96-well plate, followed by 190 μL of DPPH (1,1-diphenyl-2-picrylhydrazyl) reagent. . Thereafter, absorbance was measured at ELISA 515 nm.
그 결과, 대부분의 샘플에서 DPPH가 20% 이상 감소하였다 (도 2 참조).As a result, DPPH decreased by more than 20% in most samples (see FIG. 2).
나. 활성산소 소거능(Oxygen Radical Absorbance Capacity (ORAC) value) 측정I. Oxygen Radical Absorbance Capacity (ORAC) value measurement
복분자유의 활성산소 소거능 측정 결과는 하기 표 2에 나타낸 바와 같으며, 활성산소 소거능이 우수함을 알 수 있다.The result of measuring the active oxygen scavenging ability of Bokbun free oil is as shown in Table 2, it can be seen that the active oxygen scavenging ability is excellent.
<< 실험예Experimental Example 3> 항노화 실험 3> anti-aging experiment
가. MTT 실험 end. MTT Experiment
세포 생존도(Cell viability)를 측정하는 실험으로 황색 테트라졸리움 염 MTT(yellow tetrazolium salt MTT)는 살아있는 세포에서 물에 녹지 않는 포르마잔 결정(formazan crystal)으로 환원되는데, 이 결정을 나중에 DMSO로 녹여서 생성된 크리스탈의 양을 분광학적인 방법(Spectroscopic method)으로 측정하였다. 결국, 살아있는 세포의 수가 많을수록 이 결정의 생성도 많아지므로 이러한 방법을 통해 세포의 생존도를 쉽게 측정할 수 있다.In experiments measuring cell viability, yellow tetrazolium salt MTT is reduced to water-insoluble formazan crystals in living cells, which are later dissolved by DMSO. The amount of crystals produced was measured by the spectroscopic method. As a result, the larger the number of living cells, the greater the generation of these crystals, and thus, the viability of the cells can be easily measured through this method.
우선, HS68(human dermal fibroblast) 세포를 12-웰 플레이트에 2 X 105로 깔아놓은 후 각 웰에 MTT 용액 400 ul를 넣고 37 ℃ CO2 인큐베이터에서 2시간 반에서 3시간 가량 두었다(복분자유 추출물은 0, 1, 5, 10, 50, 100μg/mL 농도로 실험하였음). 그 후, 배지를 제거하고 여기에 DMSO를 500 ul 넣었다. 파이펫팅으로 잘 섞어준 후, 570 nm에서 흡광도를 측정하였다(도 3 참조).
First, human dermal fibroblast (HS68) cells were spread on a 12-well plate at 2 X 10 5, and 400 ul of MTT solution was added to each well, and placed in a 37 ° C. CO 2 incubator for 2 and a half hours and 3 hours (bokbunja oil extract). Was tested at concentrations of 0, 1, 5, 10, 50, 100 μg / mL). Thereafter, the medium was removed and 500 ul of DMSO was added thereto. After mixing well by pipetting, absorbance was measured at 570 nm (see FIG. 3).
나. 콜라겐 분해효소 MMP-1(Proteins of the matrix metalloproteinase) 저해효과 측정I. Inhibition of collagen degrading enzyme MMP-1 (Proteins of the matrix metalloproteinase)
웨스턴 블롯(Western blot)을 이용하여 측정하였으며, 세포주로는 인간 피부 섬유아세포인 HS68을 사용하였고, 측정샘플로는 실시예 1의 복분자씨유를 사용하였다. 구체적으로는, 24시간 동안 샘플 처리한 세포들을 배양하여 세포를 모으고, 브래드포드 어세이(Bradford assay)로 단백질을 정량하여 러닝시 로딩할 값을 결정하였다. 러닝은 스택킹 겔(stacking gel)에서는 85V로 내리다가 세퍼레이팅 겔(separating gel)에서는 100V로 2시간 정도 내렸다. 그 후 100V는 1시간 반, 110V는 1시간으로 조건을 잡아 러닝된 겔을 막으로 트랜스퍼 시켰다. 이 트랜스퍼 된 막을 MMP 54 내지 55 kD 사이즈에 맞춰 적당한 크기로 자른 후, 스킴 밀크로 블로킹을 1시간 진행하였다. 그 후 스킴 밀크에 MMP-1에 대한 항체를 1:1000으로 넣고 최소 5시간 가량 바인딩하였다. 그 과정이 끝난 후 TBST로 3번씩 10분간 세척하고, ANTI-마우스 항체를 2시간 가량 붙였다. 그 후 동일하게 TBST(mixture of tris-buffered saline and Tween 20)로 3번씩 10분간 세척하고, LAS기계를 이용해 밴드를 확인하였다.Western blot was measured using a cell line, HS68, which is a human skin fibroblast, and a sample of bokbunja seed oil of Example 1 was used. Specifically, cells were sampled for 24 hours to collect the cells, the protein was quantified by the Bradford assay to determine the value to be loaded when running. Running was reduced to 85V on a stacking gel and then to 100V on a separating gel for about 2 hours. After that, 100V was transferred to a film by running the gel under conditions of 1 and a half hours and 110V and 1 hour. The transferred membrane was cut to an appropriate size in accordance with the MMP 54 to 55 kD size, and then blocked with a scheme milk for 1 hour. After that, the antibodies to MMP-1 in the scheme milk 1: 1000 and bound for at least 5 hours. After the procedure, the cells were washed three times with TBST for 10 minutes, and ANTI-mouse antibody was added for about 2 hours. After that, the mixture was washed three times for 10 minutes with TBST (mixture of tris-buffered saline and Tween 20), and the band was identified using a LAS machine.
그 결과, 실시예 1의 복분자유에서 MMP-1 감소 효과가 우수한 것으로 나타났다[도 4 참조].
As a result, it was shown that the effect of reducing MMP-1 in bokbunja freedom of Example 1 [see Fig. 4].
<< 실험예Experimental Example 4> 4> 항아토피Anti-atopic dermatitis 실험 -β- Experiment -β- 헥소아미니다아제Hexamiminidase 저해효과 측정 Inhibitory effect measurement
실시예 2의 복분자유 5, 10, 25, 50, 100 μg/mL을 샘플로 하여 β-헥소아미니다아제 저해 효과를 다음과 같이 확인하였다.The inhibitory effect of [beta] -hexamiminidase was confirmed using the sample of 5, 10, 25, 50, 100 micrograms / mL of Bokbunbun oil of Example 2 as follows.
세포에 β-헥소아미니다아제 유도제인 A23187을 처리하면 세포 안으로 칼슘이온이 들어오게 되고, 세포 내에서 β-헥소아미니다아제가 배지로 분비된다.Treatment of cells with A23187, a β-hexamiminidase inducer, introduces calcium ions into the cells and releases β-hexamiminidase into the medium.
P-NAG 기질을 처리하여 분비된 β-헥소아미니다아제 효소와 결합하도록 하였다.P-NAG substrates were treated to bind secreted β-hexamiminidase enzyme.
종결 버퍼(Na2CO3 또는 NaHCO3) 0.1 mol 헥사아미드 효소반응으로 1시간 처리 후 ELISA로 400 nm에서 흡광도를 측정하였다[도 5 참조].The absorbance was measured at 400 nm by ELISA after 1 hour of treatment with a termination buffer (Na 2 CO 3 or NaHCO 3 ) 0.1 mol hexaamide enzyme reaction [see FIG. 5].
그 결과, 복분자유의 경우 100 μg/mL에서 β-헥소아미니다아제 방출이 30% 이상 감소하는 것으로 나타났다.
As a result, β-hexamiminidase release was reduced by more than 30% at 100 μg / mL in bokbunja oil.
제제예Formulation example 1: 캅셀제의 제조 1: Manufacture of capsule
실시에 1의 복분자유 10 ㎎Bokbun
결정성 셀룰로오스 3 ㎎3 mg of crystalline cellulose
락토오스 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 2 ㎎Magnesium Stearate 2mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
According to a conventional capsule preparation method, the above ingredients were mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4: 주사제의 제조 4: Preparation of Injection
실시에 1의 복분자유 10 ㎎Bokbun
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2794 ㎎Sterile distilled water for injection 2794 mg
Na2HPO412H2O 26 ㎎Na 2 HPO 4 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플(2 ㎖)당 상기의 성분 함량으로 주사제를 제조하였다.
Injectables were prepared at the above ingredient content per ampoule (2 mL) according to a conventional method of preparing injectables.
제제예Formulation example 6: 연고제의 제조 6: Preparation of Ointment
실시에 1의 복분자유 5 g 5 g of Bokbun free oil to conduct
세틸팔미테이트 20 g20 g of cetyl palmitate
세탄올 40 g40 g of cetanol
스테아릴알코올 40 g40 g of stearyl alcohol
미리스탄이소프로필 80 gMyristan isopropyl 80 g
모노스테아린산 소르비탄 20 g20 g of monostearate sorbitan
폴리솔베이트 60 gPolysorbate 60 g
파라옥시안식향산 프로필 1 g1 g of paraoxybenzoic acid profile
파라옥시안식향산 메틸 1 g1 g of methyl paraoxybenzoate
인산 및 정제수 적량Phosphoric Acid and Purified Water Proper
통상의 연고제 제조방법에 따라 상기 성분으로 연고제를 제조하였다.
An ointment was prepared from the above components according to a conventional ointment preparation method.
제제예Formulation example 7: 건강 음료의 제조 7: manufacture of health drinks
실시에 1의 복분자유 10 ㎎Bokbun
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g0.3 g of vitamin B2
물 적량Water quantity
통상의 건강 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 ℃에서 교반 가열 후, 만들어진 용액을 여과하여 멸균된 2 ℓ의 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강 음료를 제조하였다.After mixing the above components in accordance with a conventional method for preparing a healthy beverage, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized and then refrigerated and stored in a healthy beverage Was prepared.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층이나 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
제제예Formulation example 8: 에센스의 제조 8: Preparation of Essence
실시에 1의 복분자유 10.0 mgBokbun free oil 10.0 mg of conduct
글리세린 3.0 mgGlycerin 3.0 mg
EDTA 0.05 mgEDTA 0.05 mg
벤조페논-9 0.04 mgBenzophenone-9 0.04 mg
카르복시비닐 폴리머 0.2 mgCarboxyvinyl Polymer 0.2 mg
트리에탄올아민 0.18 mgTriethanolamine 0.18 mg
옥시도테세스-25 0.6 mgOxidoteses-25 0.6 mg
글리세릴모노스테아레이트 1.0 mgGlyceryl Monostearate 1.0 mg
방부제 0.01 mgPreservative 0.01 mg
향료 0.01 mgFragrance 0.01 mg
정제수 적량Purified water
통상의 에센스 제조방법에 따라 상기와 같은 조성으로 에센스를 제조하였다.Essence was prepared by the composition as described above according to the conventional essence manufacturing method.
Claims (13)
Bokbun free oil composition comprising a conjugated linoleic acid (CLA).
복분자유 중 총 지방산의 함량을 기준으로, 공액리놀레산의 함량이 5 내지 30 중량%인 것을 특징으로 하는 복분자유 조성물.
The method of claim 1,
Bokbun free oil composition, characterized in that the content of conjugated linoleic acid 5 to 30% by weight based on the total fatty acid content in Bokbun free oil.
상기 조성물은 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산으로 이루어진 그룹으로부터 선택되는 1종 이상을 추가로 함유하는 복분자유 조성물.
The method of claim 1,
The composition is a bokbunja oil further containing one or more selected from the group consisting of omega-3, omega-6, ellagitannins, ellagic acid, palmitic acid, stearic acid and oleic acid Composition.
상기 복분자유는 복분자씨로부터 추출된 것임을 특징으로 하는 복분자유 조성물.
The method of claim 1,
Bokbun free oil is characterized in that the extract from Bokbunja seed.
상기 조성물이 항산화, 항노화 또는 항아토피 효능을 갖는 것을 특징으로 하는 복분자유 조성물.
The method of claim 1,
Bokbunja oil composition characterized in that the composition has antioxidant, anti-aging or anti-atopic efficacy.
Conjugated linoleic acid (CLA) characterized by extracting bokbunja oil containing conjugated linoleic acid (CLA) by performing one or more extraction methods selected from the group consisting of cold pressing, hot pressing, low temperature pressing and solvent extraction Method of manufacturing bokbunja oil comprising a.
상기 추출은 오일러버형 또는 익스펠라형의 착유기를 사용하여 80 ~ 150 ℃에서 5 ~ 40분간 압착하는 것을 특징으로 하는 복분자유의 제조방법.
The method of claim 6,
The extraction method of the bokbunja free oil, characterized in that the compression for 5 to 40 minutes at 80 ~ 150 ℃ using an oil rubber or expeller type milking machine.
Health functional food comprising the bokbunja oil composition of any one of claims 1 to 5.
Food comprising the bokbunja oil composition of any one of claims 1 to 5.
Antioxidant containing the bokbunja oil composition of any one of Claims 1-5.
A medicament for preventing and treating aging or atopy, comprising the bokbunja oil composition of any one of claims 1 to 5.
A pharmaceutical for preventing and treating obesity, comprising the bokbunja oil composition of any one of claims 1 to 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090076527 | 2009-08-19 | ||
KR1020090076527 | 2009-08-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110019324A true KR20110019324A (en) | 2011-02-25 |
KR101168169B1 KR101168169B1 (en) | 2012-07-24 |
Family
ID=43776708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100054633A Active KR101168169B1 (en) | 2009-08-19 | 2010-06-10 | Rubus coreanus Miquel oil composition, use and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101168169B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140062948A (en) * | 2012-11-15 | 2014-05-27 | (주)아모레퍼시픽 | Perfume composition for expressing the fragrance of rubus coreanus miquel |
WO2015137633A1 (en) * | 2014-03-11 | 2015-09-17 | 주식회사 제이크린베리너리 | Composite extract of black raspberry oil, raspberry oil and mulberry oil |
KR20200056819A (en) * | 2018-11-15 | 2020-05-25 | 김영배 | Composition for improving skin barrier function comprising rubus coreanus miquel oil |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101828972B1 (en) * | 2015-03-30 | 2018-02-13 | (주)제이크린베리너리 | Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry |
KR20160141903A (en) | 2015-06-01 | 2016-12-12 | (주)제이크린베리너리 | Extract composition of Black raspberry for treatment and gout or blood uric acid content drop |
KR102061387B1 (en) * | 2016-03-25 | 2019-12-31 | 건국대학교 산학협력단 | Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100650016B1 (en) | 2006-04-12 | 2006-11-28 | (주)피눅스 | Separation method of antioxidant active substance from bokbunja |
-
2010
- 2010-06-10 KR KR1020100054633A patent/KR101168169B1/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140062948A (en) * | 2012-11-15 | 2014-05-27 | (주)아모레퍼시픽 | Perfume composition for expressing the fragrance of rubus coreanus miquel |
WO2015137633A1 (en) * | 2014-03-11 | 2015-09-17 | 주식회사 제이크린베리너리 | Composite extract of black raspberry oil, raspberry oil and mulberry oil |
KR20200056819A (en) * | 2018-11-15 | 2020-05-25 | 김영배 | Composition for improving skin barrier function comprising rubus coreanus miquel oil |
Also Published As
Publication number | Publication date |
---|---|
KR101168169B1 (en) | 2012-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101651833B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract of citrus preicarp | |
KR101168169B1 (en) | Rubus coreanus Miquel oil composition, use and preparation method thereof | |
KR102239784B1 (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
US8394426B2 (en) | Composition comprising an extract of hardy kiwi for preventing or treating baldness disorders or seborrheic skin disorders | |
WO2006016728A1 (en) | Composition comprising the extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders | |
KR20180077927A (en) | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof | |
WO2011043212A1 (en) | Ceramide production enhancer and moisturizing agent | |
KR101125225B1 (en) | A composition for skin wrinkle improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
KR101125224B1 (en) | A composition for skin anti-aging comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
KR20180098736A (en) | A composition having anti-oxidation or anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
KR20110130132A (en) | Antioxidant Active Composition Containing Extracts of Wildflowers and Wildflowers | |
KR100706282B1 (en) | Composition comprising dried extract having antioxidant activity | |
KR101768280B1 (en) | A composition comprising Carpinus pubescens extracts having anti-oxidation or anti-inflammation activity | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR20180098737A (en) | A composition having anti-oxidation or anti-inflammation comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
JP2004155961A (en) | Antioxidant | |
KR101256222B1 (en) | Method for removing the pigment of Red beet extract using irradiation | |
KR101430350B1 (en) | A composition comprising Decaisnea insignis extracts having anti-oxidation or anti-inflammation activity | |
KR102777268B1 (en) | Cosmethic composition for skin whitening containing essential oil of Siegesbeckia glabrescens Makino flower | |
KR102772025B1 (en) | Composition for preventing or treating bowel diseases containing Filipendula glaberrima Nakai extract as an active ingredient | |
KR101425560B1 (en) | Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient | |
KR101440483B1 (en) | Composition for antiaging comprising extract or fraction of Ardisia tinctoria Pit. as an active ingredient | |
KR101425047B1 (en) | Composition for antioxidant comprising extract or fractions of Rhododendron album Blume as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20100610 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120312 Patent event code: PE09021S01D |
|
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20120417 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120430 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20120718 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20120719 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20150714 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20150714 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160718 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20160718 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180224 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20180224 Start annual number: 6 End annual number: 6 |
|
R401 | Registration of restoration | ||
FPAY | Annual fee payment |
Payment date: 20180712 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20180712 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20190515 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20200525 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20210510 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20220421 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20230430 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20240718 Start annual number: 13 End annual number: 13 |